CYP19A1 and breast carcinoma: Despite the development of several targeted therapies (monoclonal antibodies, tyrosine-kinase and aromatase inhibitors) devised to transform breast cancer into a chronic disease, many patients show primary or acquired resistance to these anti-neoplastic drugs [39].